Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent

Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage.

Read the whole article on Physorg

More from Physorg